Jimenez-Zepeda, Victor

Hematologic Oncology

Clinical Associate Professor

Web Presence:

PubMed

Biography

Dr. Jimenez-Zepeda currently holds an academic position as Assistant Professor of Medicine at the University of Calgary and Clinician Scientist for the Tom Baker Cancer Center in Calgary, AB, Canada. He completed medical school at the University of Guadalajara in Mexico, and took Internal Medicine and Hematology training at the National Institute of Medical Sciences and Nutrition in Mexico City. He obtained specialized training in lymphoma and myeloma at the Cleveland Clinic Foundation, the Hospital Clinic in Barcelona, Spain and at the Mayo Clinic (Scottsdale, Arizona).

Dr Zepeda joined the myeloma research group at the Princess Margaret Hospital in July of 2009 as a clinical research fellow Dr Zepeda has more than 100 journal publications and abstracts to his credit. He has served as a reviewer for Journal of Clinical Oncology, American Journal of Clinical Oncology, British Journal of Hematology, Annals of Hematology, International Journal of Laboratory and Clinical Hematology, Leukemia Lymphoma Journal, Journal of Pathology and the World Journal of Surgical Procedures among others. Currently, he leads the Amyloid program at the University of Calgary. He is a member of the steering committee for the Myeloma Canada Research Network Database and is a member of the International Myeloma Society, European Hematology Association, and American Society of Hematology.

Area of Focus

  • Amyloidosis and Multiple Myeloma

Summary of Research

Number of publications: PUBMED 52 Original articles, 3 Review Articles, 4 Book Chapters Abstracts presented in major meetings: ~100 (ASH, EHA, Amyloid symposiums, etc.).

Funded Research:

  • Next generation immune treatment strategies for multiple myeloma: immune modulators in conjunction with oncolytic viral therapy, awarded by the Cancer Research Society and the Myeloma Canada Foundation, 120,000 CAD over a 2-year period (2016-2017) (Co-PI Dr Don Morris and Dr Stewart)
  • Building a comprehensive database on plasma cell disorders, co-investigator, 220,000 CAD, Co-Investigator, clinical lead, Calgary
  • Utilization of Freelite and Hevylite in the risk stratification and monitoring of patients with newly diagnosed intact immunoglobulin multiple myeloma, 24,720 CAD,
  • Co-Investigator-Multiple Myeloma Research Foundation (MMRF) Research Fellow Grant Award (75,000 USD) with the project entitled STAT3 inhibition and multiple myeloma.

Dr Zepeda has built one of the largest MGUS clinics in Canada with the aim of assessing monoclonal gammopathies of clinical significance in a more expedited fashion. He has also established an amyloid screening program in order to comprehensively evaluate patients presenting with suspected amyloidosis in a streamlined fashion.

Area Of Focus

  • Amyloidosis and Multiple Myeloma

Summary Of Research

Number of publications: PUBMED 52 Original articles, 3 Review Articles, 4 Book Chapters Abstracts presented in major meetings: ~100 (ASH, EHA, Amyloid symposiums, etc.).

Funded Research:

  • Next generation immune treatment strategies for multiple myeloma: immune modulators in conjunction with oncolytic viral therapy, awarded by the Cancer Research Society and the Myeloma Canada Foundation, 120,000 CAD over a 2-year period (2016-2017) (Co-PI Dr Don Morris and Dr Stewart)
  • Building a comprehensive database on plasma cell disorders, co-investigator, 220,000 CAD, Co-Investigator, clinical lead, Calgary
  • Utilization of Freelite and Hevylite in the risk stratification and monitoring of patients with newly diagnosed intact immunoglobulin multiple myeloma, 24,720 CAD,
  • Co-Investigator-Multiple Myeloma Research Foundation (MMRF) Research Fellow Grant Award (75,000 USD) with the project entitled STAT3 inhibition and multiple myeloma.

Dr Zepeda has built one of the largest MGUS clinics in Canada with the aim of assessing monoclonal gammopathies of clinical significance in a more expedited fashion. He has also established an amyloid screening program in order to comprehensively evaluate patients presenting with suspected amyloidosis in a streamlined fashion.